Treatment Information

Back

Brain – Glioblastoma Multiforme treatment details. Chemotherapy, Biologic therapy.

Clinical Center of the National Institutes of Health, Bethesda,MD, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:Bethesda,MD
Treatments:Chemotherapy, Biologic therapyHospital:Clinical Center of the National Institutes of Health
Drugs:Journal:Link
Date:Feb 2009

Description:

Patients:
This phase II trial involved 48 recurrent glioblastoma patients, 28 (58%) of whom were male. The median age of the group was 53 years, with a range of 21-69.

Treatment:
Patients were administered the biologic therapy bevacizumab, followed by the chemotherapy drug irinotecan.

Toxicities:
The highest toxicity grade reported was grade 4, which was for thromboembolic events including pulmonary embolism. Grade 3 hypertension (2 patients), liver problems (1 patient), and bowel perforation (1 patient) was also reported.

Results:
Median overall survival in this study was 7.1 months.

Correspondence: Dr. Howard A. Fine; email: [email protected]



Back